Clinical Trial Update: FREEDOM COVID-19 Anticoagulation Strategy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update on the FREEDOM COVID-19 Anticoagulation Strategy in COVID-19/SARS-CoV-2 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Snippet

Sponsor: Valentin Fuster | Conditions: COVID-19, SARS-CoV-2 | Phase 4 | Status: COMPLETED